STRO
Sutro Biopharma Inc

1,122
Mkt Cap
$77.47M
Volume
1.41M
52W High
$3.01
52W Low
$0.5231
PE Ratio
-0.35
STRO Fundamentals
Price
$0.8466
Prev Close
$0.91
Open
$0.88
50D MA
$0.9316
Beta
1.37
Avg. Volume
1.49M
EPS (Annual)
-$2.96
P/B
-0.89
Rev/Employee
$183,559.17
Loading...
Loading...
News
all
press releases
FY2028 EPS Estimates for Sutro Biopharma Raised by Analyst
Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Stock analysts at Wedbush lifted their FY2028 earnings per share (EPS) estimates for shares of Sutro Biopharma in a research note issued to...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Sutro Biopharma's (STRO) Neutral Rating Reaffirmed at Wedbush
Wedbush restated a "neutral" rating and issued a $2.00 target price on shares of Sutro Biopharma in a research note on Friday...
MarketBeat·12d ago
News Placeholder
Wall Street Zen Downgrades Sutro Biopharma (NASDAQ:STRO) to Sell
Wall Street Zen cut Sutro Biopharma from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·13d ago
News Placeholder
Sutro Biopharma (NASDAQ:STRO) Releases Quarterly Earnings Results, Misses Expectations By $0.28 EPS
Sutro Biopharma (NASDAQ:STRO - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·13d ago
News Placeholder
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
Sutro Biopharma (STRO) delivered earnings and revenue surprises of -59.52% and +16.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +5.41% and -5.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) delivered earnings and revenue surprises of +64.10% and +293.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of +16.42% and +1,658.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·5mo ago
News Placeholder
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·5mo ago

Latest STRO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.